Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment

Trial Profile

Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2016

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Feb 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020 as reported by ClinicalTrials.gov.
    • 04 Feb 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2020 as reported by ClinicalTrials.gov.
    • 04 Feb 2016 Planned initiation date changed from 1 Oct 2012 to 1 Jun 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top